CUE

Cue Biopharma, Inc. (CUE) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Cue Biopharma is a clinical-stage biopharmaceutical company focused on immunological disorders. Key assets include CUE-221 (anti-IgE antibody for allergic diseases, licensed from Ascendant Health) and CUE-401 (autoimmune candidate). The company executed a 1-for-30 reverse stock split effective April 23, 2026, to regain Nasdaq compliance. All share and per-share data in this report reflect the post-split basis.

Key Financial Metrics

Unusual Items: The Q2 2026 results were significantly impacted by a $90.0 million loss on the issuance of liability-classified warrants and related issuance costs. This non-cash loss arose because the fair value of warrants issued in May 2026 exceeded proceeds received due to a stock price increase between pricing and closing. Additionally, R&D expenses included a $35.1 million charge related to the Ascendant license acquisition (comprising a $15.0M cash upfront payment and non-cash warrant obligations).

Material Changes vs. Prior Period

• Revenue: Collaboration revenue increased 167% QoQ (3-month) and 302% YoY (6-month), driven by a $7.5M preclinical milestone payment from the Boehringer Ingelheim (BI) collaboration received in May 2026.
• Expenses: Operating expenses surged due to the one-time Ascendant license costs ($35.1M in R&D) and significant stock-based compensation ($23.8M total for the quarter, largely from immediate vesting of RSUs).
• Liquidity: Cash and cash equivalents decreased from $27.1M (Dec 31, 2025) to $17.4M (June 30, 2026), primarily due to the $15M upfront payment to Ascendant and general operating burn. Net cash used in operating activities was $39.9M for the six months ended June 30, 2026.
• Liabilities: Accrued expenses jumped from $1.6M to $14.9M, largely due to payroll tax liabilities associated with the RSU grants. A new $5.7M Top-Up Share Obligation liability was recorded related to the Ascendant agreement.

Guidance, Outlook, and Risks

• Capital Resources: Management states that cash on hand ($17.4M) plus proceeds from a July 2026 private placement ($49.8M) will fund operations for at least the next 12 months. The company expects to need substantial additional financing thereafter.
• Pipeline Updates:
  • CUE-221: Phase 2 trial in chronic spontaneous urticaria (China) results expected Q3 2026. IND submitted for food allergy expansion.
  • CUE-401: IND submission and Phase 1 initiation expected by end of 2026.
• Risks:
  • Going Concern: The company has a history of losses and requires additional capital to continue operations.
  • Regulatory/Geopolitical: Reliance on clinical data from Ascendant's trials in China; no assurance FDA will accept this data.
  • License Obligations: Failure to meet milestones in the Ascendant or Einstein licenses could result in termination of rights.

Investor Verification Checklist

• July 2026 Financing: Verify the closing details and terms of the $49.8M private placement mentioned in Subsequent Events to confirm runway extension.
• Warrant Accounting: Review the reclassification of May 2026 warrants from liability to equity (completed June 1, 2026) and the impact on future earnings volatility.
• Ascendant Milestones: Monitor the Phase 2 trial results in China (expected Q3 2026) which trigger significant milestone payments and potential Top-Up share issuances.
• Stock-Based Compensation: Assess the sustainability of the $23.8M SBC expense in Q2, driven by one-time RSU grants, and its impact on future burn rates.
• Reverse Split Impact: Confirm that all historical data has been properly adjusted for the 1-for-30 reverse split when comparing to prior filings.